January 16th 2024
NRX-101 is a fixed-dose combination of the broad-spectrum antibiotic D-cycloserine and lurasidone.
Expert Perspectives on Emerging CDK4/6 Inhibitor Strategies in Advanced Prostate Cancer Management Settings
View More
New York GU 17th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies
March 8-9, 2024
Register Now!
Medical Crossfire®: Expert Exchanges to Maximize Clinical Outcomes for Patients with CRPC Through Evidence-Based Personalized Therapy
View More
How the Experts Treat NMIBC During a BCG Shortage—Integrating Recent Approvals and Investigational Therapies
View More
Staying Abreast of the Prostate Cancer Treatment Paradigm From Risk Stratification to Adaptive Sequencing Strategies
View More
Everything You Need to Know About PARP Inhibitor Combinations in Prostate Cancer Care: Why? For Whom? And When?
View More
Clinical Case Vignette Series: Integrating Recent Data into Practice to Improve Outcomes in Advanced Prostate Cancer
View More
Medical Crossfire®: How Will Emerging Data Inform Treatment Planning for Patients With Prostate Cancer in the Community?
View More
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
Obesity doesn't influence need for secondary prostate cancer treatment
July 1st 2006Atlanta-In a recent study of nearly 6,500 men treated for localized pros-tate cancer, researchers found that being obese did not significantly affect the need for secondary treatment, nor did it result in decreased overall or disease-specific survival.
VEGF, TP1 may mark presence of sperm in men with NOA
July 1st 2006Chicago-A widely studied protein can help urologists find sperm to be used for in vitro fertilization and may even indicate another future pharmaceutical application of the substance, according to research presented here at the American Society of Andrology annual meeting here.
Agent may curb bone loss in men with prostate cancer
June 1st 2006Atlanta-Men who are being treated with androgen deprivation therapy for progressive prostate cancer face a second, less-recognized risk: osteoporosis and bone fracture. An initial report from a 2-year trial shows that weekly treatment with the oral bisphosphonate alendronate (Fosamax) can halt and even reverse the bone loss associated with androgen deprivation therapy.
FDA approves new delivery system for IV antibiotic
June 1st 2006The FDA recently approved a new delivery system for the antibioticcefoxitin, which is indicated for the treatment of urinary tractinfections, gynecologic infections (eg, pelvic inflammatorydisease), and a number of other common infections.
New biomaterial launched for treatment of Peyronie's disease
May 24th 2006Cook Urological introduced on Tuesday a new biomaterial known asSurgisis ES for the treatment of Peyronie's disease. Surgisis ES isa natural biomaterial that provides a graft that is strong, easy tohandle, easy to use, and biocompatible, the company said. Itsupports the growth of new fully vascularized host tissue in thepenis.
IVU honors traveling resident scholars
May 22nd 2006Chad Wallis, MD, pediatric urology fellow at the Hospital for SickChildren, Toronto, accepts congratulations from Catherine R.deVries, MD, president of International Volunteers in Urology, atthe IVU Traveling Urology Resident Scholar Reception Mondayevening.
AUA adds reimbursement, regulatory affairs department
May 22nd 2006AUA has established the Department of Reimbursement and RegulatoryAffairs to more effectively target resources and advocacy effortsfor its members. Nancy K. Edwards, currently AUA reimbursementsystems project manager, will become its director.
Difficult stones: Facts of case dictate treatment approach
May 15th 2006Brisbane, Australia-A diverse array of difficult stone cases discussed at the Urological Society of Australasia meeting here made two points very clear. First, no single treatment strategy will be appropriate for every case. Second, treatment approach should be decided upon only after comprehensively reviewing multiple factors, including the patient's age, weight, general health, and comorbidities in addition to stone size, number, and location.
Large-scale BPH studies: Data are forthcoming
May 15th 2006The major discussions of advances in understanding and treating BPHmay take place in the hallways rather than in the official meetingrooms during this month's AUA annual meeting, Claus G. Roehrborn,MD, professor and chairman of the department of urology at theUniversity of Texas Southwestern Medical Center, Dallas, toldUrology Times.
Clinicians are ignoring data on HRT and incontinence
May 1st 2006Bethesda, MD-A 2005 study from the large-scale, NIH-sponsoredWomen's Health Initiative (WHI) found that not only does hormonetherapy not relieve urinary incontinence in postmenopausal women,but estrogen (when taken alone) also doubles the risk ofincontinence in women who did not have it before they startedtherapy.
Neural network model helps predict fertility success
May 1st 2006Iowa City, IA-A neural network that takes into accountmaternal age, sperm retrieval technique, type of sperm used, andtype of male factor has been found to be clinically useful forpredicting the outcome of in vitro fertilization/intracytoplasmicsperm injection.
Drug for osteoporosis may benefit prostate cancer patients
April 6th 2006A drug typically used to treat osteoporosis has a potential clinical benefit in treating men with prostate cancer, according to researchers at the Louis Warschaw Prostate Cancer Center at Cedars-Sinai Medical Center, Los Angeles.
Pediatric PUVs may be linked to adult infertility
April 1st 2006Washington--Even after surgical ablation, posterior urethral valves (PUVs) in boys can cause bladder and kidney problems in later years. But now, for the first time, a team of pediatric urologists has shown that PUVs also can affect sex accessory glands and, ultimately, fertility. Justine M. Schober, MD, a pediatric urologist at Hamot Medical Center, Erie, PA, reported the group's findings here at the 2005 American Academy of Pediatrics Section on Urology annual meeting.
Data suggest viral, genetic roles in prostate cancer
April 1st 2006San Francisco--A never-before-seen virus associated with prostate cancer suggests that infection may play a role in the development of the disease in genetically susceptible individuals. The new virus, XMRV, is 25 times more likely to be present in prostate cancer patients with a specific genetic mutation than it is in the general male population, researchers reported at the American Society of Clinical Oncology 2006 Prostate Cancer Symposium here.
Antioxidants are not linked to decreased prostate Ca risk
March 2nd 2006Dietary or supplemental antioxidants do not appear to be associated with a decreased risk of prostate cancer among men in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial, suggests a study published last month in the Journal of the National Cancer Institute (2006; 98:245-54).
Psychological therapies may benefit CP/CPPS patients
March 1st 2006Baltimore--Psychological treatment, particularly cognitive behavioral therapy, can help ease chronic pain. That's why these therapies may be able to do the same for chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) patients, argued Judith Turner, PhD, at the NIDDK-sponsored Chronic Pelvic Pain/Chronic Prostatitis Scientific Workshop here.
Genetics could explain chronic pelvic pain
March 1st 2006Baltimore?What causes chronic pain in chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS)? This could be the wrong question to ask, said Jeffrey S. Mogil, PhD, at the NIDDK-sponsored Chronic Pelvic Pain/Chronic Prostatitis Scientific Workshop. The better question may be: Why do these particular men have chronic pain, whereas others do not?